The HVTN 702 phase 2b-3 HIV-1 vaccine trial assesses the preventive vaccine efficacy, safety, and tolerability of ALVAC/gp120 + MF59 vaccines in South African adults. Dr Zoe Moodie (Fred Hutchinson Cancer Center, Seattle, WA, USA) joins touchINFECTIOUSDISEASES to discuss the aims and results of the HVTN 702 trials and their implications for future research.
The presentation entitled ‘Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T cell correlates of HIV-1 acquisition risk’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
Questions:
- Could you tell us a little about the ALVAC/gp120 + MF59 vaccines? (00:25)
- What did the HVTN 702 clinical trials teach us about the efficacy and safety of the ALVAC/gp120 + MF59 vaccines? (01:25)
- What were the aims of the current analysis? (01:52)
- What were the findings and what are their implications for future research? (02:21)
Disclosures: Zoe Moodie has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
